IL320024A - מעכב perk hc-5404 בשילוב עם נוגדן אנטי-pd-1 ו/או חומר אנטי אנגיוגנטי לשימוש בטיפול בסרטן - Google Patents

מעכב perk hc-5404 בשילוב עם נוגדן אנטי-pd-1 ו/או חומר אנטי אנגיוגנטי לשימוש בטיפול בסרטן

Info

Publication number
IL320024A
IL320024A IL320024A IL32002425A IL320024A IL 320024 A IL320024 A IL 320024A IL 320024 A IL320024 A IL 320024A IL 32002425 A IL32002425 A IL 32002425A IL 320024 A IL320024 A IL 320024A
Authority
IL
Israel
Prior art keywords
effective amount
antibody
therapeutically effective
combination
cancer treatment
Prior art date
Application number
IL320024A
Other languages
English (en)
Original Assignee
Hibercell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hibercell Inc filed Critical Hibercell Inc
Publication of IL320024A publication Critical patent/IL320024A/he

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL320024A 2022-10-04 2023-10-04 מעכב perk hc-5404 בשילוב עם נוגדן אנטי-pd-1 ו/או חומר אנטי אנגיוגנטי לשימוש בטיפול בסרטן IL320024A (he)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263413116P 2022-10-04 2022-10-04
US202363443344P 2023-02-03 2023-02-03
US202363455911P 2023-03-30 2023-03-30
PCT/US2023/076006 WO2024077099A1 (en) 2022-10-04 2023-10-04 Perk inhibitor hc-5404 in combination with anti-pd-1 antibody and/or an antiangiogenetic agent for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
IL320024A true IL320024A (he) 2025-06-01

Family

ID=88690304

Family Applications (1)

Application Number Title Priority Date Filing Date
IL320024A IL320024A (he) 2022-10-04 2023-10-04 מעכב perk hc-5404 בשילוב עם נוגדן אנטי-pd-1 ו/או חומר אנטי אנגיוגנטי לשימוש בטיפול בסרטן

Country Status (9)

Country Link
EP (1) EP4598523A1 (he)
JP (1) JP2025533802A (he)
KR (1) KR20250078561A (he)
CN (1) CN120787153A (he)
AU (1) AU2023356307A1 (he)
CA (1) CA3269342A1 (he)
IL (1) IL320024A (he)
MX (1) MX2025004037A (he)
WO (1) WO2024077099A1 (he)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121399099A (zh) * 2023-03-30 2026-01-23 希伯塞尔股份有限公司 (r)-2-氨基-5-(4-(2-(3,5-二氟苯基)-2-羟基乙酰胺基)-2-甲基苯基)-n-异丙基烟酰胺的晶形及其使用方法
WO2025137710A1 (en) * 2023-12-22 2025-06-26 Hibercell, Inc. Methods of treating cancer using combinations of gcn2 modulators and belzutifan

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3095156A1 (en) * 2018-03-26 2019-10-03 Icahn School Of Medicine At Mount Sinai Methods of treating minimal residual cancer
WO2020142694A2 (en) * 2019-01-03 2020-07-09 Musc Foundation For Research Development Ero1-alpha inhibitors
CN112807434B (zh) * 2020-12-30 2022-04-05 中山大学 Perk抑制剂在制备肝癌药物的增效剂中的应用

Also Published As

Publication number Publication date
JP2025533802A (ja) 2025-10-09
WO2024077099A1 (en) 2024-04-11
CA3269342A1 (en) 2024-04-11
KR20250078561A (ko) 2025-06-02
AU2023356307A1 (en) 2025-04-10
CN120787153A (zh) 2025-10-14
EP4598523A1 (en) 2025-08-13
MX2025004037A (es) 2025-05-02

Similar Documents

Publication Publication Date Title
IL273188B (he) טיפול בשילוב של מעכבי קולטן כימוקין 2 (ccr2) ומעכב pd-1/pd-l1
IL320024A (he) מעכב perk hc-5404 בשילוב עם נוגדן אנטי-pd-1 ו/או חומר אנטי אנגיוגנטי לשימוש בטיפול בסרטן
JOP20220163A1 (ar) مركب بيريدازينيل-ثيازول كربوكساميد
IL300151A (he) צירופים לטיפול בסרטן
EP4643882A3 (en) Capsid inhibitors for the prevention of hiv
JOP20230118A1 (ar) مركب كربوكساميد أريل غير متجانس
WO2016133903A3 (en) Combination therapy for cancer treatment
EP4353747A3 (en) Combination of zanubrutinib with an anti-cd20 or an anti-pd-1 antibody for use in treating cancer
RU2014111069A (ru) Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
FI3493812T3 (fi) Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten
JP2019533715A5 (he)
RU2020109376A (ru) Применение антагонистов рецептора ep4 для лечения nash- ассоциированного рака печени
RU2014144254A (ru) Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение
WO2020132560A3 (en) Compositions and methods for cancer therapy
JP2016537380A5 (he)
EE200200565A (et) Vaskulaarse kahjustava toimega kombinatsioonravi
PE20221768A1 (es) Inhibidores de egfr
WO2019136157A3 (en) Reducing beta-catenin and ido expression to potentiate immunotherapy
WO2023240082A3 (en) Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active agent for treating cancer
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака
FI3646869T3 (fi) Solunsalpaajahoito atsabisykloyhdisteellä syövän hoitamiseksi
MX2021006210A (es) Metodos para diagnosticar y/o tratar una hepatopatia, nefropatia o neumopatia aguda o cronica.
JP2022513029A5 (he)
JOP20210221A1 (ar) علاجات مشتركة لاستخدامها في علاج السرطان